# A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

> **NCT03780543** · PHASE2 · TERMINATED · sponsor: **Assembly Biosciences** · enrollment: 92 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)

## Key facts

- **NCT ID:** NCT03780543
- **Lead sponsor:** Assembly Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-20
- **Primary completion:** 2021-04-26
- **Final completion:** 2021-04-26
- **Target enrollment:** 92 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2023-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03780543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03780543, "A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03780543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*